Biophytis - Live Healthier Longer

Biophytis - Live Healthier Longer company information, Employees & Contact Information

Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging. Our small molecules are aimed at stimulating biological resilience to stress during aging. Ruvembri - in regulatory and clinical phases - is our leading drug candidate is administered orally:
 • for the treatment of severe respiratory events related to COVID-19 following positive results in Phase 2/3 clinical study (COVA) • for the treatment of reduced mobility in elderly patients with sarcopenia, with promising results in a Phase 2 clinical study (SARA) conducted in the United States and Europe
 A pediatric formulation of Ruvembri is being developed with IND granted in the US and Belgium (MYODA) for the treatment of Duchenne Muscular Dystrophy (DMD).

Company Details

Employees
23
Founded
-
Address
4, Place Jussieu, Paris,ile De France 75005,france
Phone
+33 1 44 27 23 00
Industry
Biotechnology
HQ
Paris, Ile de France
Looking for a particular Biophytis - Live Healthier Longer employee's phone or email?

Biophytis - Live Healthier Longer Questions

News

Biophytis Unveils Its Outlook Strategies for 2025 - Yahoo Finance

Biophytis Unveils Its Outlook Strategies for 2025 Yahoo Finance

Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity - Yahoo Finance

Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity Yahoo Finance

Biophytis and AskHelpU sign co-development agreement to treat rare neuromuscular diseases in China - BioSpectrum Asia

Biophytis and AskHelpU sign co-development agreement to treat rare neuromuscular diseases in China BioSpectrum Asia

Biophytis is Deploying its Partnership Strategy in Obesity - Stock Titan

Biophytis is Deploying its Partnership Strategy in Obesity Stock Titan

FDA approves Biophytis’ Phase II OBA obesity study - Clinical Trials Arena

FDA approves Biophytis’ Phase II OBA obesity study Clinical Trials Arena

Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial - The Lancet

Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial The Lancet

Why Biophytis S.A. (Common Stock) (6XB2) stock is favored by hedge funds - July 2025 Volume & Low Risk High Reward Ideas - Trung tâm Dự báo KTTV quốc gia

Why Biophytis S.A. (Common Stock) (6XB2) stock is favored by hedge funds - July 2025 Volume & Low Risk High Reward Ideas Trung tâm Dự báo KTTV quốc gia

Biophytis (BPTS) Stock Price, News & Analysis - MarketBeat

Biophytis (BPTS) Stock Price, News & Analysis MarketBeat

Why Is Biophytis (BPTS) Stock Up 49% Today? - InvestorPlace

Why Is Biophytis (BPTS) Stock Up 49% Today? InvestorPlace

Biophytis applies to commence “first ever” Phase 3 sarcopenia trial - Longevity.Technology

Biophytis applies to commence “first ever” Phase 3 sarcopenia trial Longevity.Technology

Biophytis Announces Receipt of Nasdaq Notice - Stock Titan

Biophytis Announces Receipt of Nasdaq Notice Stock Titan

Biophytis files for FDA authorisation for first Phase III sarcopenia study - Clinical Trials Arena

Biophytis files for FDA authorisation for first Phase III sarcopenia study Clinical Trials Arena

Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe - Yahoo Finance

Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe Yahoo Finance

Why Biophytis S.A. (Common Stock) (6XB2) stock is favored by hedge funds - 2025 Price Momentum & Low Risk High Reward Ideas - Trung tâm Dự báo KTTV quốc gia

Why Biophytis S.A. (Common Stock) (6XB2) stock is favored by hedge funds - 2025 Price Momentum & Low Risk High Reward Ideas Trung tâm Dự báo KTTV quốc gia

Why Biophytis S.A. (Common Stock) (6XB2) stock is favored by hedge funds - 2025 Trading Recap & Real-Time Price Movement Reports - Trung tâm Dự báo KTTV quốc gia

Why Biophytis S.A. (Common Stock) (6XB2) stock is favored by hedge funds - 2025 Trading Recap & Real-Time Price Movement Reports Trung tâm Dự báo KTTV quốc gia

Biophytis Reinforces Leadership Teams with Three Senior Appointments - Yahoo Finance

Biophytis Reinforces Leadership Teams with Three Senior Appointments Yahoo Finance

Is Biophytis S.A. (6XB3) stock a defensive play amid uncertainty - 2025 Key Highlights & Real-Time Volume Analysis Alerts - Trung tâm Dự báo KTTV quốc gia

Is Biophytis S.A. (6XB3) stock a defensive play amid uncertainty - 2025 Key Highlights & Real-Time Volume Analysis Alerts Trung tâm Dự báo KTTV quốc gia

Aug Levels: Is Biophytis S.A. (6XB3) stock attractive for growth funds - July 2025 Chart Watch & Risk Controlled Stock Pick Alerts - Trung tâm Dự báo KTTV quốc gia

Aug Levels: Is Biophytis S.A. (6XB3) stock attractive for growth funds - July 2025 Chart Watch & Risk Controlled Stock Pick Alerts Trung tâm Dự báo KTTV quốc gia

Top Biophytis - Live Healthier Longer Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant